Publications 2025

Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Ferreira AC, Neelon B, Guttridge DC, Ostrowski MC, Zimmers TA, Nielsen D (2025)
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
J Clin Oncol, JCO2301965 (in press)
DOI 10.1200/JCO.23.01965, PubMed 40354592

Dajani O, Philips I, Størkson EK, Balstad TR, Brown LR, Bye A, Dolan R, Greil C, Hjermstad M, Jakobsen G, Kaasa S, McDonald J, Ottestad I, Sayers J, Simpson M, Sousa MS, Vagnildhaug OM, Yule MS, Laird BJA, Skipworth RJE, Solheim TS, Stares M, Arends J, Cancer Cachexia Endpoints Working Group (2025)
Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series
J Cachexia Sarcopenia Muscle, 16 (2), e13756
DOI 10.1002/jcsm.13756, PubMed 40065459

Ghadimi M, Pelzer U, Besselink MG, Siveke J, Telgmann R, Braren R, Wilmink H, Crede M, Koenig A, Koenig U, Liffers ST, Antweiler K, Uijterwijk B, Seppanen H, Nordin A, Puolakkainen P, Dajani OF, Labori KJ, Johansson M, Bratlie SO, Friede T, Jo P (2025)
Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial
BMC Cancer, 25 (1), 208
DOI 10.1186/s12885-025-13573-7, PubMed 39915735

Hustad KS, Koteng LH, Urrizola A, Arends J, Bye A, Dajani O, Deliens L, Fallon M, Hjermstad MJ, Kohlen M, Kurita GP, Lundeby T, Mitrea N, Payne C, Roselló-Keränen S, Warmbrodt N, de Wilde A, Kaasa S, de Vos-Geelen J, Laird BJA, MyPath consortium (2025)
Practical cancer nutrition, from guidelines to clinical practice: a digital solution to patient-centred care
ESMO Open, 10 (4), 104529
DOI 10.1016/j.esmoop.2025.104529, PubMed 40179818

Publications 2024

Brown LR, Sousa MS, Yule MS, Baracos VE, McMillan DC, Arends J, Balstad TR, Bye A, Dajani O, Dolan RD, Fallon MT, Greil C, Hjermstad MJ, Jakobsen G, Maddocks M, McDonald J, Ottestad IO, Phillips I, Sayers J, Simpson MR, Vagnildhaug OM, Solheim TS, Laird BJA, Skipworth RJE, Cancer Cachexia Endpoints Working Group (2024)
Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series
J Cachexia Sarcopenia Muscle, 15 (3), 816-852
DOI 10.1002/jcsm.13478, PubMed 38738581

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjærde OC, Tveit KM, Spindler KG, Pallisgaard N, Kure EH (2024)
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer
Clin Colorectal Cancer, 24 (2), 153-158
DOI 10.1016/j.clcc.2024.11.004, PubMed 39743478

Hjermstad MJ, Jakobsen G, Arends J, Balstad TR, Brown LR, Bye A, Coats AJS, Dajani OF, Dolan RD, Fallon MT, Greil C, Grzyb A, Kaasa S, Koteng LH, May AM, McDonald J, Ottestad I, Philips I, Roeland EJ, Sayers J, Simpson MR, Skipworth RJE, Solheim TS, Sousa MS, Vagnildhaug OM et al. (2024)
Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series
J Cachexia Sarcopenia Muscle, 15 (3), 794-815
DOI 10.1002/jcsm.13453, PubMed 38553255

Hjermstad MJ, Pirnat A, Aass N, Andersen S, Astrup GL, Dajani O, Garresori H, Guldhav KV, Hamre H, Haukland EC, Jordal F, Lundeby T, Løhre ET, Mjåland S, Paulsen Ø, Semb KA, Staff ES, Wester T, Kaasa S (2024)
PALLiative care in ONcology (PALLiON): A cluster-randomised trial investigating the effect of palliative care on the use of anticancer treatment at the end of life
Palliat Med, 38 (2), 229-239
DOI 10.1177/02692163231222391, PubMed 38193250

Urrizola A, Dajani O, Aass N, Bjerkeset E, Hjermstad MJ, Kaasa S, Klepstad P, Pirnat A, Raaness I, Steinsheim H, Bye A (2024)
Nutrition impact symptom monitoring and weight loss outcomes: a longitudinal radiotherapy study
BMJ Support Palliat Care (in press)
DOI 10.1136/spcare-2024-004939, PubMed 38862183

Vagnildhaug OM, Balstad TR, Ottestad I, Bye A, Greil C, Arends J, Baracos V, Brown LR, Dajani OF, Dolan RD, Fallon M, Fraser E, Grzyb A, Hjermstad MJ, Jakobsen G, Kaasa S, McDonald J, Philips I, Sayers J, Simpson MR, Sousa MS, Skipworth RJE, Laird BJA, Solheim TS, Cancer Cachexia Endpoints Working Group (2024)
Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series
J Cachexia Sarcopenia Muscle, 15 (2), 513-535
DOI 10.1002/jcsm.13434, PubMed 38343065

Westgaard A, Pirnat A, Hjermstad MJ, Aass N, Kaasa S, Dajani OF (2024)
Prognostic Value of Performance Status, Albumin, and CRP in Last-Line Chemotherapy for Pancreatic vs. Other Gastrointestinal Cancers-Simple Tools Matter
Curr Oncol, 31 (9), 5462-5471
DOI 10.3390/curroncol31090404, PubMed 39330032

Yule MS, Thompson J, Leesahatsawat K, Sousa MS, Anker SD, Arends J, Balstad TR, Brown LR, Bye A, Dajani O, Fallon M, Hjermstad MJ, Jakobsen G, McDonald J, McGovern J, Roeland EJ, Sayers J, Skipworth RJE, Ottestad IO, Philips I, Simpson MR, Solheim TS, Vagnildhaug OM, McMillan D, Laird BJA et al. (2024)
Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series
J Cachexia Sarcopenia Muscle, 15 (3), 853-867
DOI 10.1002/jcsm.13491, PubMed 38783477

Publications 2023

Lundereng ED, Nes AAG, Holmen H, Winger A, Thygesen H, Jøranson N, Borge CR, Dajani O, Mariussen KL, Steindal SA (2023)
Health Care Professionals' Experiences and Perspectives on Using Telehealth for Home-based Palliative Care: Scoping Review
J Med Internet Res, 25, e43429
DOI 10.2196/43429, PubMed 36989024

McDonald J, Sayers J, Anker SD, Arends J, Balstad TR, Baracos V, Brown L, Bye A, Dajani O, Dolan R, Fallon MT, Fraser E, Griel C, Grzyb A, Hjermstad M, Jamal-Hanjani M, Jakobsen G, Kaasa S, McMillan D, Maddocks M, Philips I, Ottestad IO, Reid KF, Sousa MS, Simpson MR et al. (2023)
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series
J Cachexia Sarcopenia Muscle, 14 (5), 1932-1948
DOI 10.1002/jcsm.13321, PubMed 37671529

Publications 2022

Lundeby T, Finset A, Kaasa S, Wester TE, Hjermstad MJ, Dajani O, Wist E, Aass N (2022)
A complex communication skills training program for physicians providing advanced cancer care - content development and barriers and solutions for implementation
J Commun Healthc, 16 (1), 46-57
DOI 10.1080/17538068.2022.2039468, PubMed 36919800

Publications 2021

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer, 149 (6), 1385-1397
DOI 10.1002/ijc.33672, PubMed 33961700

Hjermstad MJ, Hamfjord J, Aass N, Dajani O, Lundeby T, Wester T, Kaasa S (2021)
Using Process Indicators to Monitor Documentation of Patient-Centred Variables in an Integrated Oncology and Palliative Care Pathway-Results from a Cluster Randomized Trial
Cancers (Basel), 13 (9)
DOI 10.3390/cancers13092194, PubMed 34063594

Lundereng ED, Nes AAG, Holmen H, Winger A, Thygesen H, Jøranson N, Borge CR, Chen W, Dajani O, Mariussen KL, Steindal SA (2021)
Health Care Professionals' Experiences and Perspectives on Using Telehealth for Home-Based Palliative Care: Protocol for a Scoping Review
JMIR Res Protoc, 10 (10), e33305
DOI 10.2196/33305, PubMed 34714254

Publications 2020

Hjermstad MJ, Aass N, Andersen S, Brunelli C, Dajani O, Garresori H, Hamre H, Haukland EC, Holmberg M, Jordal F, Krogstad H, Lundeby T, Løhre ET, Mjåland S, Nordbø A, Paulsen Ø, Schistad Staff E, Wester T, Kaasa S, Loge JH (2020)
PALLiON - PALLiative care Integrated in ONcology: study protocol for a Norwegian national cluster-randomized control trial with a complex intervention of early integration of palliative care
Trials, 21 (1), 303
DOI 10.1186/s13063-020-4224-4, PubMed 32241299

Publications 2019

Hamfjord J, Guren TK, Dajani O, Johansen JS, Glimelius B, Sorbye H, Pfeiffer P, Lingjærde OC, Tveit KM, Kure EH, Pallisgaard N, Spindler KG (2019)
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy
Ann Oncol, 30 (7), 1088-1095
DOI 10.1093/annonc/mdz139, PubMed 31046124

Publications 2017

Sternby Eilard M, Hagström H, Mortensen KE, Wilsgaard T, Vagnildhaug OM, Dajani O, Stål P, Rizell M (2017)
Quality of life as a prognostic factor for survival in hepatocellular carcinoma
Liver Int, 38 (5), 885-894
DOI 10.1111/liv.13593, PubMed 28941130

Publications 2015

Gupta S, Argilés G, Munster PN, Hollebecque A, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Piha-Paul SA (2015)
A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Clin Cancer Res, 21 (23), 5235-44
DOI 10.1158/1078-0432.CCR-15-0180, PubMed 26187616

Piha-Paul SA, Munster PN, Hollebecque A, Argilés G, Dajani O, Cheng JD, Wang R, Swift A, Tosolini A, Gupta S (2015)
Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours
Eur J Cancer, 51 (14), 1865-73
DOI 10.1016/j.ejca.2015.06.115, PubMed 26199039

Wesseltoft-Rao N, Hjermstad MJ, Ikdahl T, Dajani O, Ulven SM, Iversen PO, Bye A (2015)
Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer
Nutr Cancer, 67 (3), 472-80
DOI 10.1080/01635581.2015.1004728, PubMed 25710201

Publications 2012

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T (2012)
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
J Clin Oncol, 30 (15), 1755-62
DOI 10.1200/JCO.2011.38.0915, PubMed 22473155

Tveteraas IH, Müller KM, Aasrum M, Ødegård J, Dajani O, Guren T, Sandnes D, Christoffersen T (2012)
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells
J Exp Clin Cancer Res, 31 (1), 72
DOI 10.1186/1756-9966-31-72, PubMed 22967907

Publications 2011

Müller KM, Tveteraas IH, Aasrum M, Ødegård J, Dawood M, Dajani O, Christoffersen T, Sandnes DL (2011)
Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells
BMC Cancer, 11, 421
DOI 10.1186/1471-2407-11-421, PubMed 21961726

Publications 2008

Dajani OF, Meisdalen K, Guren TK, Aasrum M, Tveteraas IH, Lilleby P, Thoresen GH, Sandnes D, Christoffersen T (2008)
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes
J Cell Physiol, 214 (2), 371-80
DOI 10.1002/jcp.21205, PubMed 17654493

Publications 2007

Meisdalen K, Dajani OF, Christoffersen T, Sandnes D (2007)
Prostaglandins enhance epidermal growth factor-induced DNA synthesis in hepatocytes by stimulation of E prostanoid 3 and F prostanoid receptors
J Pharmacol Exp Ther, 322 (3), 1044-50
DOI 10.1124/jpet.107.121277, PubMed 17567965

Publications 2005

Guren TK, Christoffersen T, Thoresen GH, Wisløff F, Dajani O, Tveit KM (2005)
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568

Nilssen LS, Dajani O, Christoffersen T, Sandnes D (2005)
Sustained diacylglycerol accumulation resulting from prolonged G protein-coupled receptor agonist-induced phosphoinositide breakdown in hepatocytes
J Cell Biochem, 94 (2), 389-402
DOI 10.1002/jcb.20260, PubMed 15526278

Publications 2002

Melien O, Nilssen LS, Dajani OF, Sand KL, Iversen JG, Sandnes DL, Christoffersen T (2002)
Ca2+-mediated activation of ERK in hepatocytes by norepinephrine and prostaglandin F2 alpha: role of calmodulin and Src kinases
BMC Cell Biol, 3, 5
DOI 10.1186/1471-2121-3-5, PubMed 11914123

Publications 2001

Dajani O (2001)
The role of phospholipid signaling in regulation of hepatocyte growth
Department of Pharmacology, Faculty of Medicine, University of Oslo, [Oslo], 1 b. (flere pag.)
BIBSYS 010807837, ISBN 82-7633-159-9

Publications 1999

Dajani OF, Sandnes D, Melien O, Rezvani F, Nilssen LS, Thoresen GH, Christoffersen T (1999)
Role of diacylglycerol (DAG) in hormonal induction of S phase in hepatocytes: the DAG-dependent protein kinase C pathway is not activated by epidermal growth factor (EGF), but is involved in mediating the enhancement of responsiveness to EGF by vasopressin, angiotensin II, and norepinephrine
J Cell Physiol, 180 (2), 203-14
DOI 10.1002/(SICI)1097-4652(199908)180:2<203::AID-JCP8>3.0.CO;2-T, PubMed 10395290

Sandnes D, Dajani O, Bjørneby A, Christoffersen T (1999)
The relationship between activation of phosphoinositide-specific phospholipase C and growth stimulation by Ca2+-mobilizing hormones in hepatocytes
Pharmacol Toxicol, 84 (5), 234-40
DOI 10.1111/j.1600-0773.1999.tb01488.x, PubMed 10361980

Publications 1996

Dajani OF, Røttingen JA, Sandnes D, Horn RS, Refsnes M, Thoresen GH, Iversen JG, Christoffersen T (1996)
Growth-promoting effects of Ca(2+)-mobilizing agents in hepatocytes: lack of correlation between the acute activation of phosphoinositide-specific phospholipase C and the stimulation of DNA synthesis by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2 alpha
J Cell Physiol, 168 (3), 608-17
DOI 10.1002/(SICI)1097-4652(199609)168:3<608::AID-JCP13>3.0.CO;2-V, PubMed 8816915

Guren TK, Thoresen GH, Dajani OF, Taraldsrud E, Moberg ER, Christoffersen T (1996)
Epidermal growth factor behaves as a partial agonist in hepatocytes: effects on DNA synthesis in primary culture and competition with transforming growth factor alpha
Growth Factors, 13 (3-4), 171-9
DOI 10.3109/08977199609003219, PubMed 8919025

Publications 1995

Refsnes M, Dajani OF, Sandnes D, Thoresen GH, Røttingen JA, Iversen JG, Christoffersen T (1995)
On the mechanisms of the growth-promoting effect of prostaglandins in hepatocytes: the relationship between stimulation of DNA synthesis and signaling mediated by adenylyl cyclase and phosphoinositide-specific phospholipase C
J Cell Physiol, 164 (3), 465-73
DOI 10.1002/jcp.1041640304, PubMed 7650056

Thoresen GH, Refsnes M, Dajani OF, Johansen EJ, Christoffersen T (1995)
Dexamethasone inversely regulates DNA synthesis and phosphoenolpyruvate carboxykinase mRNA levels in cultured rat hepatocytes: interactions with insulin, glucagon, and transforming growth factor beta 1
Pharmacol Toxicol, 76 (3), 163-70
DOI 10.1111/j.1600-0773.1995.tb00124.x, PubMed 7617540

Publications 1994

Dajani OF, Refsnes M, Guren TK, Horn RS, Thoresen GH, Christoffersen T (1994)
Elevated glucose concentrations inhibit DNA synthesis and expression of c-myc in cultured hepatocytes
Biochem Biophys Res Commun, 202 (3), 1476-82
DOI 10.1006/bbrc.1994.2097, PubMed 8060330

Refsnes M, Thoresen GH, Dajani OF, Christoffersen T (1994)
Stimulation of hepatocyte DNA synthesis by prostaglandin E2 and prostaglandin F2 alpha: additivity with the effect of norepinephrine, and synergism with epidermal growth factor
J Cell Physiol, 159 (1), 35-40
DOI 10.1002/jcp.1041590106, PubMed 8138589

Publications 1992

Refsnes M, Thoresen GH, Sandnes D, Dajani OF, Dajani L, Christoffersen T (1992)
Stimulatory and inhibitory effects of catecholamines on DNA synthesis in primary rat hepatocyte cultures: role of alpha 1- and beta-adrenergic mechanisms
J Cell Physiol, 151 (1), 164-71
DOI 10.1002/jcp.1041510121, PubMed 1313818

Publications 1990

Thoresen GH, Sand TE, Refsnes M, Dajani OF, Guren TK, Gladhaug IP, Killi A, Christoffersen T (1990)
Dual effects of glucagon and cyclic AMP on DNA synthesis in cultured rat hepatocytes: stimulatory regulation in early G1 and inhibition shortly before the S phase entry
J Cell Physiol, 144 (3), 523-30
DOI 10.1002/jcp.1041440321, PubMed 2167904